Allogene therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Allogene therapeutics Contact Number

Contact Us Allogene

5 hours ago Allogene.com Show details

650-457-2700

Want to learn more about Allogene Therapeutics? Please contact us by phone at 650-457-2700 or by email at [email protected]allogene.com.

1. 210 E Grand Ave, South San Francisco, CA 94080 · (650) 457-2700DIRECTIONSWEBSITE

Category: Contact SupportShow more

Allogene Therapeutics: Allogeneic Cell Therapy

5 hours ago Allogene.com Show details

A highly experienced management team that includes key pioneers of CAR T cell therapy. Approximately 275 employees singularly focused on the development of AlloCAR T™ therapy. Allogene is proud to have approximately 50% of our senior leadership team …

Category: Cell PhoneShow more

Allogene Therapeutics Information Allogene Therapeutics

9 hours ago Rocketreach.co Show details

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors.

Employees: 122 ( View all )
Ticker: ALLO
Revenue: $88.6 million

Category: Contact NumberShow more

Allogene Therapeutics, Inc. Company Profile South San

9 hours ago Dnb.com Show details

(650) 457-2700

Allogene Therapeutics, Inc. is located in South San Francisco, CA, United States and is part of the Scientific Research and Development Services Industry. Allogene Therapeutics, Inc. has 122 total employees across all of its locations.

Employees: 122
Phone: (650) 457-2700
Location: 210 E Grand Ave, South San Francisco, 94080-4811, CA

Category: Contact NumberShow more

Information About Allogene Therapeutics

3 hours ago Allogene.com Show details

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development

Category: Contact NumberShow more

Allogene Therapeutics Company Profile Office Locations

8 hours ago Craft.co Show details

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer. The Company's portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T therapy candidate currently in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

Category: Contact NumberShow more

David Chang's email & phone Allogene Therapeutics's

Just Now Rocketreach.co Show details

David Chang's email address d*****@allogene.com Show email & phone number >>> Rocketreach finds email, phone & social media for 450M+ professionals. Try for free at rocketreach.co

Category: Phone NumberShow more

Allogene Therapeutics Crunchbase Company Profile & Funding

1 hours ago Crunchbase.com Show details

Contact Email [email protected]allogene.com. Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates

Category: Contact NumberShow more

Careers Allogene Therapeutics: Allogeneic Cell Therapy

2 hours ago Allogene.com Show details

CAREERS. At Allogene, you'll find an experienced, high-performance, and growing team of employees whose sole focus is to transform the treatment of cancer. Our deep pipeline of innovative AlloCAR T™ therapies is based on an allogeneic platform enabled by validated gene editing and advanced proprietary cell-manufacturing technologies.

Category: Cell PhoneShow more

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR

6 hours ago Globenewswire.com Show details

The conference ID number for the live call is 9746209. About Allogene Therapeutics Allogene Media/Investor Contact:

Category: Contact NumberShow more

FDA halts all Allogene cell therapy trials after

9 hours ago Medcitynews.com Show details

Pharma, BioPharma. FDA halts all Allogene cell therapy trials after chromosome problem detected All of Allogene Therapeutics’ clinical trials are now under an FDA clinical hold.

Category: Cell PhoneShow more

FDA halts Allogene blood cancer trials after abnormality

7 hours ago Statnews.com Show details

FDA halts Allogene blood cancer trials after patient found to have ‘chromosomal abnormality’. A llogene Therapeutics said Thursday that the …

Category: Contact NumberShow more

Allogene Therapeutics Reports Second Quarter 2021

8 hours ago Ir.allogene.com Show details

The conference ID number for the live call is 8080137. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene Therapeutics

Category: Contact NumberShow more

Allogene Therapeutics and SpringWorks Therapeutics

Just Now Ir.allogene.com Show details

(714) 552-0326

Allogene Media/Investor Contact: Christine Cassiano Chief Communications Officer (714) 552-0326 [email protected]allogene.com. SpringWorks Media/Investor Contact: Kim Diamond Vice President, Communications and Investor Relations 203-561 …

Category: Contact NumberShow more

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR

8 hours ago Finance.yahoo.com Show details

The conference ID number for the live call is 9746209. About Allogene Therapeutics Allogene Media/Investor Contact:

Category: Contact NumberShow more

Terms of Use for Allogene Therapeutics

7 hours ago Allogene.com Show details

Allogene disclaims any intention or obligation to update any forward-looking statements. 1. Acceptance of the Terms and Conditions. 1.1 Allogene Therapeutics (herein referred to as the “Company,” “we,” “us” or “our”). “Company” with the actual company name and/or provides and makes available this web site (the “Web Site”).

Category: Contact NumberShow more

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR

Just Now Morningstar.com Show details

The conference ID number for the live call is 9746209. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in …

Category: Contact NumberShow more

FDA Places Clinical Hold on Select Allogeneic CAR T Trials

7 hours ago Onclive.com Show details

The FDA has placed a hold on clinical trials examining Allogene Therapeutics, Inc.’s allogeneic CAR T-cell therapies for patients with cancer, following a report of …

Category: Contact NumberShow more

Allogene Therapeutics Reports Second Quarter 2019

9 hours ago Ir.allogene.com Show details

The conference ID number for the live call is 4851687. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene Therapeutics

Category: Contact NumberShow more

Allogene Therapeutics Reports First Quarter 2021 Financial

7 hours ago Ir.allogene.com Show details

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter ended March 31, 2021.

Category: Contact NumberShow more

Allogene cell therapy trials halted by FDA after

5 hours ago Biopharmadive.com Show details

Dive Brief: The Food and Drug Administration has halted testing for a group of cancer cell therapies from Allogene Therapeutics after a "chromosomal abnormality" was observed in a single patient who received one of the treatments, the biotech said in an announcement Thursday afternoon.; According to Allogene, a patient who received ALLO-501a, the biotech's most advanced, …

Category: Cell PhoneShow more

Allogene Therapeutics: I Am Buying On The Clinical Hold Dip

9 hours ago Seekingalpha.com Show details

Allogene Therapeutics: I Am Buying On The Clinical Hold Dip Oct. 11, 2021 12:00 PM ET Allogene Therapeutics, Inc. (ALLO) 8 Comments 5 Likes Avisol Capital Partners

Category: Contact NumberShow more

How Do Analysts Feel About Allogene Therapeutics Inc

4 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 134.83 million. ALLO does have institutional investors; and they hold 61.60% of the stock. Allogene Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 4 new insider purchases involving 34,362 shares.

Category: Contact NumberShow more

Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Intrinsic

3 hours ago Finance.yahoo.com Show details

Check out our latest analysis for Allogene Therapeutics Crunching the numbers We use what is known as a 2-stage model, which simply means we have two different periods of …

Category: Contact NumberShow more

Should I Buy Allogene Therapeutics, Inc. (ALLO)?

Just Now Finance.yahoo.com Show details

Allogene Therapeutics, Inc. (NASDAQ: ALLO) was in 19 hedge funds' portfolios at the end of March. The all time high for this statistic is 24. ALLO has experienced an increase in hedge fund

1. Author: Debasis Saha

Category: Contact NumberShow more

Allogene Therapeutics Reports Second Quarter 2021

Just Now Finance.yahoo.com Show details

The conference ID number for the live call is 8080137. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in …

Category: Contact NumberShow more

AlloMek

Just Now Allomek.com Show details

AlloMek. Our Focus & Lead Candidate: CIP-137401. Our approach is simple, uncomplicated. With our expertise in medicinal chemistry and molecular modeling, we understand drug design, and understand how to build molecules that are unique and drug-like. With bold vision, AlloMek has applied advanced and proprietary technology

Category: Contact NumberShow more

Allogene Therapeutics, Inc. (Form: 8K, Received: 10/15

3 hours ago Content.edgar-online.com Show details

714-552-0326

About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer. # # # Allogene Media/Investor Contact: Christine Cassiano Chief Communications Officer 714-552-0326

Category: Contact NumberShow more

Premarket Mover: Allogene Therapeutics Inc (ALLO) Up 2.89%

6 hours ago Investorsobserver.com Show details

Allogene Therapeutics Inc has a Long-Term Technical rank of 0. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 100% of the market scoring higher. In the Biotechnology industry which is number 134 by this metric, ALLO ranks better than 0% of stocks. Important Dates for Investors in ALLO:

Category: Contact NumberShow more

ALLOGENE THERAPEUTICS, INC. : Shareholders Board Members

5 hours ago Marketscreener.com Show details

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.

Category: Contact NumberShow more

Allogene Therapeutics, Inc. (ALLO) Stock Price, News

5 hours ago Stockstelegraph.com Show details

Allogene Therapeutics, Inc. (ALLO) stock plummeted over -4.02% intraday to trade at $16.48 a share on NASDAQ. The stock opened with a gain of 0.23% at $17.21 and touched an intraday high of $17.34, rising 0.99% against the last close of $17.17.

Category: Contact NumberShow more

Allogene Therapeutics Employees, Board Members, Advisors

8 hours ago Crunchbase.com Show details

Employee Profiles. Number of Employee Profiles 5. Allogene Therapeutics has 5 current employee profiles, including Chief Executive Officer and Co-Founder David Chang. David Chang Chief Executive Officer and Co-Founder. David Chang President, CEO and Co-Founder. Joshua Kazam Co-Founder. Robert To Associate Director, External Testing Oversight.

Category: Contact NumberShow more

Allogene Therapeutics Reports Third Quarter 2020 Financial

7 hours ago Ir.allogene.com Show details

The conference ID number for the live call is 2637139. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene Therapeutics

Category: Contact NumberShow more

Allogene Therapeutics Inc. (NASDAQ: ALLO)’s Stock Market

7 hours ago Marketingsentinel.com Show details

In the last trading session, 8.66 million shares of the Allogene Therapeutics Inc. (NASDAQ:ALLO) were traded. Most recently the company’s share price was $13.46, and it changed around $0.33 or 2.51% from the last close, which brings the market valuation of the company to $3.55B. ALLO currently tra

Category: Contact NumberShow more

Allogene Therapeutics Reports First Quarter 2021 Financial

9 hours ago Finance.yahoo.com Show details

The conference ID number for the live call is 9435559. stockholders’ equity1,069,779 1,079,617 Allogene Media/Investor Contact: Christine Cassiano Chief Communications Officer (714) 552 …

Category: Contact NumberShow more

Veer Bhavnagri Net Worth, Biography & Insider Trading History

7 hours ago Insidertrades.com Show details

(650) 457-2700

The corporate mailing address for Mr. Bhavnagri and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]

Category: Contact NumberShow more

What 5 Analyst Ratings Have To Say About Allogene Therapeutics

8 hours ago Benzinga.com Show details

According to 5 analyst offering 12-month price targets in the last 3 months, Allogene Therapeutics has an average price target of $32.8 with a high of …

Category: Contact NumberShow more

CARsgen Therapeutics Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Show details

Contact Email [email protected] Phone Number +862154489928 CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers.

Category: Contact NumberShow more

Allogene Therapeutics Funding, Financials, Valuation

Just Now Crunchbase.com Show details

Allogene Therapeutics has raised a total of $531.8M in funding over 2 rounds. Their latest funding was raised on Sep 7, 2018 from a Convertible Note round. Allogene Therapeutics is registered under the ticker NASDAQ:ALLO . Their stock opened with $18.00 in its Oct 11, 2018 IPO. Allogene Therapeutics is funded by 14 investors.

Category: Contact NumberShow more

Kite Pharma Wikipedia

1 hours ago En.wikipedia.org Show details

Allogene Therapeutics. Following the sale of Kite to Gilead, Kite's founders and its CMO struck a deal in February 2018 with Pfizer to develop CAR-T therapeutics, leading to the creation of Allogene Therapeutics. The three former Kite executives subsequently hired into Allogene a number of people who left Kite after its sale.

Category: Contact NumberShow more

Allogene Therapeutics : Reports FDA Clinical Hold of

Just Now Marketscreener.com Show details

The conference ID number for the live call is 9746209. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene Therapeutics

Category: Contact NumberShow more

Contact Nimble Therapeutics

9 hours ago Nimbletherapeutics.com Show details

Please complete the form below to be connected with the appropriate contact at Nimble Therapeutics. REASON FOR INQUIRY. DESCRIPTION OF INQUIRY. FIRST NAME. LAST NAME. COMPANY. EMAIL. PHONE. Submit inquiry. Where we work. 603 Science Dr Madison, WI, USA 53711. On the web. LinkedIn. Where You Can Find Us. 18 - 19 October

Category: Contact SupportShow more

CRSP Stock Tumbles As Analysts Pit Its GeneEdited Drug

8 hours ago Investors.com Show details

But Crispr, Allogene and Fate Therapeutics are attempting to use donor cells, a process called allogeneic. Crispr unveiled test results for 26 lymphoma patients who received its drug, dubbed

Category: Contact NumberShow more

American Society of Clinical Oncology (ASCO) Abstract

1 hours ago Globenewswire.com Show details

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric …

Category: Contact NumberShow more

Allogene Therapeutics Inc. (ALLO) Vs CRISPR Therapeutics

9 hours ago Netcials.com Show details

The growth in the percentage of a stock is a key metric for investment decisions. Let us compare the growth of Allogene Therapeutics Inc. and CRISPR Therapeutics AG stocks over 1-year, 3-year, 5-year and 10-year periods. Table1: Growth of Allogene Therapeutics Inc. (ALLO)

Category: Contact NumberShow more

What Is So Great About Allogene Therapeutics Inc. (ALLO

5 hours ago Marketingsentinel.com Show details

Investors are also buoyed by the number of investors in a company, with Allogene Therapeutics Inc. having a total of 286 institutions that hold shares in the company. The top two institutional holders are Tpg Group Holdings (sbs) Advisors, Inc. with over 18.72 million shares worth more than $488.12 million.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is allogene therapeutics?

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.

Who is the chief executive officer of allogene?

David Chang, MD, PhD, is the President, Chief Executive Officer and Co-Founder of Allogene. He previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company.

How is allogeneic cell therapy used in cancer treatment?

The Potential to Forever Change How Cancer is Treated. Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T TM) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes...

How to get a job at allogenecom?

We are on our way to building a culture and a company focused on working collaboratively to do something life-changing for cancer patients. If you are interested in joining us in the next revolution in the field of cancer, please send your resume to [email protected]

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Amgen
Att
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes